Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.48 |
| ▸ | CASP6 | P55212 | 10/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 10/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390697 | 1.00 | CASP3 (0.48) | CASP3CASP6CASP8CASP7CTSK | |
| SCHEMBL22390736 | 0.94 | CTSK (0.51) | CASP3CASP6CASP8CASP7CTSK | |
| SCHEMBL22390738 | 0.94 | CTSK (0.51) | CASP3CASP6CASP8CASP7CTSK | |
| SCHEMBL22404750 | 0.87 | CTSK (0.47) | CASP3CASP6CASP8CASP7CTSK | |
| SCHEMBL22404667 | 0.84 | KLK7 (0.47) | CASP3CASP6CASP8 | |
| SCHEMBL22404792 | 0.82 | PPARA (0.52) | CASP3CASP6CASP8CTSS | |
| SCHEMBL22404745 | 0.82 | KLK7 (0.46) | CASP3CASP6CASP8CTSKCTSV | |
| SCHEMBL22390677 | 0.79 | PPARG (0.43) | CTSKCTSS | |
| SCHEMBL22390674 | 0.79 | PPARG (0.43) | CTSKCTSS | |
| SCHEMBL30220135 | 0.78 | CACNA1B (0.44) | CASP3CASP6CASP8CTSKCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | CASP3 2/4885CASP6 8/4885CASP8 9/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | CASP3 2/4885CASP6 8/4885CASP8 9/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | CASP3 2/4885CASP6 8/4885CASP8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.